C&G Editor in Chief, Erin Harris

  1. Navigating CGT Biotech's Financial Headwinds And The Path Forward 4/24/2025

    Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.

  2. How Cynata Therapeutics is Unlocking the Power of iPSCs to Transform Regenerative Medicine 4/11/2025

    Cynata Therapeutics is pioneering a scalable, iPSC-based platform to produce consistent, high-quality MSCs that are showing strong clinical promise across multiple indications, including GvHD, diabetic foot ulcers, and osteoarthritis.

  3. Emerging Technologies For Cell Therapy Manufacturing 4/7/2025

    This summary of the Cell & Gene Live, Emerging Technologies in Cell Therapy Manufacturing, explains why automation, robotics, AI, and digital tools offer a clear path to scalable, efficient, and patient-centric manufacturing.

  4. Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center 3/13/2025

    Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.

  5. Tessera Therapeutics Advances In Vivo Gene Therapy For SCD 1/30/2025

    Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from of the Bill & Melinda Gates Foundation to support their efforts.

  6. 2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC 12/4/2024

    Leaders from Kiji Therapeutics, Precision Biosciences, and Orgenesis weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond.

  7. CD70 & Autoimmune Diseases 11/26/2024

    Allogene Therapeutics' Dr. Zachary Roberts shares the clinical-stage biotech's rationale behind selecting CD70 as a target for activated T cells in autoimmune diseases.

  8. Neogene's Focus On Off-The-Shelf TCR Therapies 10/31/2024

    This recap of Episode 87 of Cell & Gene: The Podcast shares Neogene Therapeutics' Carsten Linnemann, Ph.D.'s take on why "off-the-shelf" will make t-cell receptor therapies more accessible to patients.

  9. Highlights From ARM's 2024 Meeting On The Mesa 10/25/2024

    ARM's 2024 Meeting on the Mesa has concluded. Here are a few brief highlights from this year's conference.

  10. Global Regulatory Challenges Of Rare Diseases 9/26/2024

    ISCT's Chief Regulatory Officer, Dr. Bambi Grilley, shares insights from the 2024 Global Regulatory Summit.